Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-
93) - payment and coding for laboratory tests
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Duration: September 16, 2011
to
August 31, 2018
General Issues: Medicare/Medicaid , Medical/Disease Research/Clinical Labs , Copyright/Patent/Trademark , Health Issues
Spending: about $4,340,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2011: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Centers For Medicare and Medicaid Services (CMS),, House of Representatives,, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB),, Executive Office of the President (EOP), U.S. Senate,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Kimberly Linthicum
Leg Director, Rep Bob Franks (1997-2000)
Leg Director, Rep Bob Franks (1997-2000)
Leg Correspondent, Rep Charles Taylor (1997)
Leg Correspondent, Rep Bill Martini (1995-1996)
Leg Director, Rep Bob Franks (1997-2000) Leg Correspondent, Rep Charles Taylor (1997) Leg Correspondent, Rep Bill Martini (1995-1996)
" "
Leg Correspondent, Rep Charles Taylor (1997)
Leg Correspondent, Rep Bill Martini (1995-1996)
Kelly Nickel
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2018
Myriad Genetic Laboratories, Inc. in-house lobbying effort was terminated on Oct. 16, 2018
Original Filing: 300985908.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-
93) - payment and coding for laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2018
Myriad Genetic Laboratories, Inc. in-house lobbying effort was terminated on Sept. 4, 2018
Original Filing: 300981461.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-
93) - payment and coding for laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2018
In Q2, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on July 20, 2018.
Original Filing: 300975229.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-
93) - payment and coding for laboratory tests
Billing rules for laboratory tests; date of service rule/14 day rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2018
In Q1, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on April 20, 2018.
Original Filing: 300955968.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-
93) - payment and coding for laboratory tests
Billing rules for laboratory tests; date of service rule/14 day rule
National Coverage Decision on next generation sequencing tests
HR 5062 - Advancing Access to Precision Medicine Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2017
In Q4, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2018.
Original Filing: 300936329.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-
93) - payment and coding for laboratory tests
Billing rules for laboratory tests; date of service rule/14 day rule
CLFS CY2018 Preliminary Determinations
National Coverage Decision on next generation sequencing tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2017
In Q3, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2017.
Original Filing: 300916203.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-
93) - payment and coding for laboratory tests
Billing rules for laboratory tests; date of service rule/14 day rule
CLFS CY2018 Preliminary Determinations
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Health & Human Services - Dept of (HHS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2017
Myriad Genetic Laboratories, Inc. amended a lobbying report for in-house lobbying in Q32017 on Oct. 20, 2017
Original Filing: 300916220.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-
93) - payment and coding for laboratory tests
Billing rules for laboratory tests; date of service rule/14 day rule
CLFS CY2018 Preliminary Determinations
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB) Health & Human Services - Dept of (HHS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2017
In Q2, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300896568.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-
93) - payment and coding for laboratory tests
Coverage of laboratory developed test under specific LCD
Billing rules for laboratory tests; date of service rule/14 day rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2017
In Q1, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300876662.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-
93) - payment and coding for laboratory tests
Coverage of laboratory developed test under specific LCD
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2016
In Q4, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2017.
Original Filing: 300853730.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
CY2017 Clinical Lab Fee Schedule rates; reconsideration process
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests,
Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2016
In Q3, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2016.
Original Filing: 300839108.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
CY2016 Clinical Lab Fee Schedule amounts - Gapfill process
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests,
21st Century Cures (HR 6),
Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2016
In Q2, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on July 20, 2016.
Original Filing: 300819386.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics,
21st Century Cures (HR 6),
Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2016
In Q1, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on April 20, 2016.
Original Filing: 300800865.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics,
21st Century Cures (HR 6),
Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2015
In Q4, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300782916.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
CY2016 CLFS Payment Determinations
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics,
21st Century Cures (HR 6),
Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2015
In Q3, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2015.
Original Filing: 300764600.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics,
21st Century Cures (HR 6),
Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2015
In Q2, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on July 20, 2015.
Original Filing: 300745065.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
21st Century Cures (HR 6)
Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2015
In Q1, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on April 16, 2015.
Original Filing: 300717394.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
21st Century Cures Discussion Draft; Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2014
In Q4, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2015.
Original Filing: 300706245.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
PL 112-29 - America Invents Act; implementation of the Genetic Testing Study
S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2014
In Q3, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2014.
Original Filing: 300683346.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
PL 112-29 - America Invents Act; implementation of the Genetic Testing Study
S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2014
Myriad Genetic Laboratories, Inc. amended a lobbying report for in-house lobbying in Q32014 on Oct. 20, 2014
Original Filing: 300683648.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
PL 112-29 - America Invents Act; implementation of the Genetic Testing Study
S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2014
Myriad Genetic Laboratories, Inc. amended a lobbying report for in-house lobbying in Q22014 on Oct. 20, 2014
Original Filing: 300683769.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; Medicare payment for clinical laboratory tests; proposals to change fee schedule adjustments
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2014
In Q2, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on July 21, 2014.
Original Filing: 300668978.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; Medicare payment for clinical laboratory tests; proposals to change fee schedule adjustments
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2014
In Q1, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on April 21, 2014.
Original Filing: 300648263.xml
Lobbying Issues
HR 4302 - Protecting Access to Medicare Act of 2014; Medicare payment for clinical laboratory tests; proposals to change fee schedule adjustments
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
S.1720 - Patent Transparency and Improvements Act of 2013; issues related to gene patents
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2013
In Q4, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2014.
Original Filing: 300626592.xml
Lobbying Issues
Medicare payment for clinical laboratory tests; legisaltive proposals to change current statute including copays, coinsurance, fee schedule adjustments, etc. (no legislation introduced)
Medicare payment for certain classes of laboratory tests (MAAAs) (no legislation introduced)
Medicare payment for molecular pathology codes (no legislation introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
March-in rights request to NIH; no legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Affordable Care Act; implementation of Preventive benefits
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Oct. 21, 2013.
Original Filing: 300604939.xml
Lobbying Issues
Medicare payment for clinical laboratory tests; legisaltive proposals to change current statute including copays, coinsurance, fee schedule adjustments, etc. (no legislation introduced)
Medicare payment for certain classes of laboratory tests (MAAAs) (no legislation introduced)
Medicare payment for molecular pathology codes (no legislation introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
March-in rights request to NIH; no legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Affordable Care Act; implementation of Preventive benefits
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2013
In Q2, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on July 22, 2013.
Original Filing: 300585034.xml
Lobbying Issues
Medicare payment for clinical laboratory tests; legisaltive proposals to change current statute including copays, coinsurance, fee schedule adjustments, etc. (no legislation introduced)
Medicare payment for certain classes of laboratory tests (MAAAs) (no legislation introduced)
Medicare payment for molecular pathology codes (no legislation introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
TRICARE Laboratory Developed Test (LDT) Demonstration Project; implementation of demo
Affordable Care Act; Preventive benefits
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2013
In Q1, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on April 22, 2013.
Original Filing: 300560139.xml
Lobbying Issues
Medicare payment for clinical laboratory tests; legisaltive proposals to change current statute including copays, coinsurance, fee schedule adjustments, etc. (no legislation introduced)
Medicare payment for certain classes of laboratory tests (MAAAs) (no legislation introduced)
Medicare payment for molecular pathology codes (no legislation introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced)
Agencies Lobbied
U.S. Senate U.S. House of Representatives,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
TRICARE Laboratory Developed Test (LDT) Demonstration Project; implementation of demo
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2012
Myriad Genetic Laboratories, Inc. amended a lobbying report for in-house lobbying in Q42012 on Oct. 21, 2013
Original Filing: 300605015.xml
Lobbying Issues
Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P) - Fee schedule placement of genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests
Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB),
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
TRICARE Laboratory Developed Test (LDT) Demonstration Project; implementation of demo
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2012
In Q4, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2013.
Original Filing: 300539733.xml
Lobbying Issues
Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P) - Fee schedule placement of genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests
Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB),
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
TRICARE Laboratory Developed Test (LDT) Demonstration Project; implementation of demo
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Oct. 17, 2012.
Original Filing: 300515188.xml
Lobbying Issues
Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P) - Fee schedule placement of genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests
Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Management & Budget (OMB),
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2012
In Q2, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on July 19, 2012.
Original Filing: 300493022.xml
Lobbying Issues
Medicare funding for and beneficiary cost-sharing under Clinical Lab Fee Schedule (The Middle Class Tax Relief & Job Creation Act, PL 112-96 and Budget Control Act of 201, PL 112-225)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
Legislation to reauthorize Medical Device User Fee Act (S. 3187, Food and Drug Administration Safety and Innovation Act); laboratory developed test (LDT) requirements
FDA draft guidance to regulate laboratory developed tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
America Invents Act (PL 112-29); implementation of the Genetic Testing Study
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2012
In Q1, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on April 19, 2012.
Original Filing: 300468501.xml
Lobbying Issues
Medicare funding and beneficiary cost-sharing under Clinical Lab Fee Schedule in The Middle Class Tax Relief & Job Creation Act of 2012 (HR 3630, PL 112-96)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation to regulate clinical labs (HR 3207, Modernizing Laboratory Test Standards for Patients Act of 2011); full bill
Legislation to reauthorize Medical Device User Fee Act (not yet introduced); laboratory developed test (LDT) requirements
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA, PL 111-148) - preventive services benefit
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2011
In Q4, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2012.
Original Filing: 300452264.xml
Lobbying Issues
Budget Control Act (PL 112-25) - proposals to create copays for clinical lab tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 3207 - legislation to regulate clinical labs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA, PL 111-148) - preventive services benefit
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2011
In Q3, Myriad Genetic Laboratories, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2011.
Original Filing: 300428748.xml
Lobbying Issues
Budget Control Act (PL 112-25) - proposals to create copays for clinical lab tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Draft legislation imposing FDA regulation on clinical labs (not yet introduced)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA, PL 111-148) - preventive services benefit
3rd Quarter, 2011
Myriad Genetic Laboratories, Inc. filed a lobbying registration on Oct. 16, 2011 for in-house lobbying efforts, effective Sept. 16, 2011.
Original Filing: 300416082.xml
Issue(s) they said they’d lobby about: Budget Control Act (PL 112-25)
Legislation to regulate Laboratory Developed Tests (LDTs) (not yet introduced)
PPACA - Patient Protection and Affordable Care Act (PL 111-148)
AIA - American Invents Act (PL 112-29) .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate